Αποτελέσματα Αναζήτησης
31 Ιουλ 2024 · New analysis from an extension trial confirmed the efficacy of REXULTI in treating patients with agitation associated with dementia due to Alzheimer's disease. The analysis explored clinically meaningful response (CMR) among patients over 12 and 24 weeks (NCT03548584 and NCT03594123), defined by a 20-point score reduction from baseline in Cohen ...
In patients with agitation in Alzheimer dementia, treatment with brexpiprazole (fixed doses of 2 or 3 mg) resulted in statistically significant greater improvements vs placebo in CMAI total score (primary end point) and CGI-S score as related to agitation (key secondary end point), supported by all other secondary efficacy end points.
31 Αυγ 2018 · Background: Dementia represents a mental and economic burden for both patients and their caregivers. Therefore, the aim of this study is to explore the effectiveness of animal assisted therapy (AAT) with special focus on canis therapy among people with dementia, specifically Alzheimer’s disease.
13 Σεπ 2021 · According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans.
27 Ιουν 2024 · Rexulti was the first medicine approved by the FDA for reducing symptoms of agitation in dementia due to Alzheimer’s disease. How Does the Medicine Work?
12 Μαΐ 2023 · The U.S. Food and Drug Administration (FDA) this week approved the expanded use of Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD).
11 Μαΐ 2023 · Today, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to...
